BACKGROUND: A pilot safety study of focused microwave phased array thermotherapy in the treatment of primary breast carcinomas was conducted. METHODS: Ten patients with breast carcinomas beneath the skin surface that ranged in maximal clinical size from 1 to 8 cm (mean, 4.3 cm) were treated with the breast compressed in the prone position. We planned to deliver a tumor thermal dose equivalent to 60 minutes at 43 degrees C. Breast imaging and pathology data were used to assess efficacy. RESULTS: For the 10 patients, the mean tumor equivalent thermal dose was 51.7 minutes, the mean peak tumor temperature was 44.9 degrees C, and the mean treatment time was 34.7 minutes. Ultrasound imaging demonstrated a significant reduction in tumor size (mean, 41%) 5 to 18 days after thermotherapy in 6 (60%) of 10 patients. A significant tumor response on the basis of reduction in tumor size or significant tumor cell kill occurred in 8 (80%) of 10 patients. CONCLUSIONS: With sufficient skin cooling, delivery of focused microwave phased array thermotherapy is safe in treating breast carcinomas when used alone, and some potential efficacy was demonstrated at the tumor thermal doses administered. Increased tumor thermal dose efficacy studies in larger patient populations for improved breast conservation should be investigated.
BACKGROUND: A pilot safety study of focused microwave phased array thermotherapy in the treatment of primary breast carcinomas was conducted. METHODS: Ten patients with breast carcinomas beneath the skin surface that ranged in maximal clinical size from 1 to 8 cm (mean, 4.3 cm) were treated with the breast compressed in the prone position. We planned to deliver a tumor thermal dose equivalent to 60 minutes at 43 degrees C. Breast imaging and pathology data were used to assess efficacy. RESULTS: For the 10 patients, the mean tumor equivalent thermal dose was 51.7 minutes, the mean peak tumor temperature was 44.9 degrees C, and the mean treatment time was 34.7 minutes. Ultrasound imaging demonstrated a significant reduction in tumor size (mean, 41%) 5 to 18 days after thermotherapy in 6 (60%) of 10 patients. A significant tumor response on the basis of reduction in tumor size or significant tumor cell kill occurred in 8 (80%) of 10 patients. CONCLUSIONS: With sufficient skin cooling, delivery of focused microwave phased array thermotherapy is safe in treating breast carcinomas when used alone, and some potential efficacy was demonstrated at the tumor thermal doses administered. Increased tumor thermal dose efficacy studies in larger patient populations for improved breast conservation should be investigated.
Authors: Justin P McWilliams; Edward W Lee; Shota Yamamoto; Christopher T Loh; Stephen T Kee Journal: Semin Intervent Radiol Date: 2010-09 Impact factor: 1.513
Authors: Stijn van Esser; Maurice A A J van den Bosch; Paul J van Diest; Willem Th M Mali; Inne H M Borel Rinkes; Richard van Hillegersberg Journal: World J Surg Date: 2007-12 Impact factor: 3.352
Authors: Earl Zastrow; Shakti K Davis; Mariya Lazebnik; Frederick Kelcz; Barry D Van Veen; Susan C Hagness Journal: IEEE Trans Biomed Eng Date: 2008-12 Impact factor: 4.538
Authors: Rache M Simmons; Karla V Ballman; Charles Cox; Ned Carp; Jennifer Sabol; Rosa F Hwang; Deanna Attai; Michael Sabel; David Nathanson; Andrew Kenler; Linsey Gold; Cary Kaufman; Linda Han; Aaron Bleznak; J Stanley Smith; Dennis Holmes; Bruno Fornage; Carisa Le-Petross; Syed Hoda; Linda McCall; Kelly K Hunt Journal: Ann Surg Oncol Date: 2016-05-24 Impact factor: 5.344
Authors: S van Esser; G Stapper; P J van Diest; M A A J van den Bosch; J H G M Klaessens; W P Th M Mali; I H M Borel Rinkes; R van Hillegersberg Journal: Ann Surg Oncol Date: 2009-06-09 Impact factor: 5.344